Physicochemical Properties
Molecular Formula | C4H5N3O2 |
Molecular Weight | 127.10 |
Exact Mass | 127.038 |
CAS # | 932-53-6 |
PubChem CID | 70269 |
Appearance | White to off-white solid powder |
Density | 1.7±0.1 g/cm3 |
Melting Point | 210-212°C |
Index of Refraction | 1.692 |
LogP | -2.05 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 0 |
Heavy Atom Count | 9 |
Complexity | 196 |
Defined Atom Stereocenter Count | 0 |
InChi Key | XZWMZFQOHTWGQE-UHFFFAOYSA-N |
InChi Code | InChI=1S/C4H5N3O2/c1-2-3(8)5-4(9)7-6-2/h1H3,(H2,5,7,8,9) |
Chemical Name | 6-methyl-2H-1,2,4-triazine-3,5-dione |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | 6-Azathymine inhibits the growth of Streptococcus faecalis (8043) and a number of other microbial strains in a competitive manner. Research on 6-Azathymine's mode of action shows that S. The analog can be changed by faecalis into azathymidine, the equivalent deoxyriboside[2]. |
ln Vivo | When the mouse is given 6-Azathymine, both free and different metabolites of the drug are eliminated through the urine. After mice are given 6-Azathymine-5-14C, radioactivity is discovered in every tissue examined. This radioactivity can be identified as metabolic byproducts as well as free Azathymine[3]. |
References |
[1]. Purification, Characterization and Inhibition of D-3-aminoisobutyrate Aminotransferase From the Rat Liver. Eur J Biochem. 1990 Apr 20;189(1):39-45. [2]. Effect of the Deoxyriboside of 6-azathymine (Azathymidine) on the Biosynthesis of Deoxyribonucleic Acid by Bone Marrow and Neoplastic Cells (In Vitro). Biochim Biophys Acta. 1956 Apr;20(1):209-14. [3]. Studies on the Metabolism of Thymine and 6-azathymine. Biochem Pharmacol. Apr-May 1962;11:323-36. [4]. In vitro and in vivo antiviral (RNA) evaluation of orotidine 51-monophosphatedecarboxylase inhibitors and analogues including 6-azauridine-51-(ethylmethoxyalaninyl)phosphate (a 51-monophosphate prodrug). Antiviral Chemistry & Chemotherapy (1994) 5(4), 209-220. |
Additional Infomation | 6-azathymine is a nucleobase analogue that is thymine in which the CH group at position 6 is replaced by nitrogen. It has a role as a Mycoplasma genitalium metabolite and an EC 2.6.1.40 [(R)-3-amino-2-methylpropionate--pyruvate transaminase] inhibitor. It is a cyclic ketone, a member of 1,2,4-triazines and a nucleobase analogue. |
Solubility Data
Solubility (In Vitro) | DMSO : 125 mg/mL (983.48 mM) |
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 7.8678 mL | 39.3391 mL | 78.6782 mL | |
5 mM | 1.5736 mL | 7.8678 mL | 15.7356 mL | |
10 mM | 0.7868 mL | 3.9339 mL | 7.8678 mL |